Mauricio Chaparro

Mauricio Chaparro

Auto-generated profile, based on publicly available information

Mauricio Chaparro

14 Pedriatic Hematopoietic Stem Cell Transplantation, HOMI Misericordia Foundation Hospital, Bogota, Colombia

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2025 in JCO Global Oncology
Verified
Journal Article
Closed access
GVGabriela Villanueva
Gabriela Villanueva
SASandra Alarcón
Sandra Alarcón
DBDiana Bonilla
Diana Bonilla
ACAlejandra Casanovas
Alejandra Casanovas
MCMauricio Chaparro
Mauricio Chaparro
MVMilena Villarroel
Milena Villarroel
PURPOSE: To develop a Latin American expert consensus to support, guide, and accelerate the approval and equitable access to anti-GD2 immunotherapy for patients with high-risk neuroblastoma (HR-NB) in the region. Survival rates for HR-NB have improved with the incorporation of anti-GD2 immunotherapy; however, despite the approval of two commercial anti-GD2 therapies in two countries, access remains limited in Latin America. METHODS AND RESULTS: A systematic review was conducted of studies published from January 2004 through February 2025. Of 401 studies identified, 29 met inclusion criteria and served as the basis for four expert consensus statements on the use of anti-GD2 immunotherapy: (1) Newly diagnosed HR-NB maintenance therapy: Anti-GD2 immunotherapy as maintenance treatment for all newly diagnosed HR-NB patients is strongly recommended to maximize event-free survival and reduce the need for morbid and costly salvage therapies. (2) Relapsed/refractory NB: Early integration (at first relapse) of anti-GD2 immunotherapy in salvage treatment is recommended. (3) Role of high-dose chemotherapy with autologous stem-cell transplant (ASCT): Some argue that anti-GD2 immunotherapy obviates the need for ASCT. However, until results of randomized trials omitting ASCT are available, the panel recommends continued use of ASCT where it is available. (4) Newly diagnosed HR-NB: incorporation of anti-GD2 during induction/consolidation: Pilot studies using early anti-GD2 immunotherapy plus chemotherapy showed promising results but is not recommended until confirmed by larger studies with well-defined control arms. CONCLUSION: This consensus highlights the urgent need to expand access to anti-GD2 therapy in Latin America as maintenance therapy for newly diagnosed patients with HR-NB and patients with relapsed or refractory neuroblastoma. Collaboration between health policymakers, the pharmaceutical industry, the Global Platform for Access to Childhood Cancer Medicines, and the pediatric oncology community is essential to address this challenge.

21 May 2026
Verified
Journal Article
Open access
JRJulian Rojas
Julian Rojas
CACarlos A. Arango-Franco
Carlos A. Arango-Franco
MMMarcela Moncada-Velez
Marcela Moncada-Velez
DADiana Marcela Arboleda
Diana Marcela Arboleda
EFEdgar Alfonso Figueredo
Edgar Alfonso Figueredo
AAAndrés Augusto Arias
Andrés Augusto Arias
CGD is an inborn error of immunity caused by pathogenic variants in genes encoding the phagocyte NADPH oxidase complex. In a multicenter cohort of 39 Colombian patients, we define clinical, microbiological, and genetic features, expanding the regional variant spectrum and highlighting the need for earlier diagnosis and improved access to specialized testing.